2 Tahun 2020
17
BioTrends Vol.11 No.2 Tahun 2020
gen untuk HER2 (Burness et sebagai sel kanker payudara bergantian, penting untuk
al., 2010; Seal & Chia, 2010). basal (Toft & Cryns, 2011). dicatat bahwa keduanya
Oleh karena itu, subtipe Meskipun istilah TNBC dan tidak sama (Alluri &
TNBC juga digolongkan basal digunakan secara Newman, 2014).
18
BioTrends Vol.11 No.2 Tahun 2020
Gambar 2. Morfologi
sel kanker payudara
MDA-MB-231 (ATCC,
2020)
19
BioTrends Vol.11 No.2 Tahun 2020
20
BioTrends Vol.11 No.2 Tahun 2020
(Neve et al., 2006). Sel pengujian terkait ekspresi berupa lapisan lapis tunggal
SKBR3 memiliki fenotip dan amplifikasi gen HER2 (monolayer) yang adherent
seperti sel epitel dengan (Emlet et al., 2006). HER2 atau menempel pada dasar
karakteristik molekuler dapat memediasi aktivasi flask (Gambar 3), sedangkan
berupa ekspresi gen untuk jalur sinyaling MAPK dan dalam kultur sel 3D bentuk
ER dan PR yang rendah serta PI3K/AKT yang berperan morfologinya seperti anggur
HER2 yang tinggi (ER-, PR-, penting dalam migrasi dan dengan sedikit kontak
HER2+). Karena tingginya survival sel (Merkhofer et al., antarsel (ATTC, 2020; Kenny
ekspresi HER2 secara 2010). et al., 2007).
endogen pada SKBR3, sel ini Karakteristik
sering kali digunakan sebagai pertumbuhan SKBR3 dalam
kontrol positif dalam sel kultur dua dimensi (2D)
Gambar 3. Morfologi
sel kanker payudara
SKBR3 (ATCC, 2020)
Sel SKBR3 diketahui memiliki Sel SKBR3 diketahui kerusakan DNA serta
kemampuan adaptasi yang memiliki kemampuan tingginya ekspresi gen-gen
tinggi terhadap berbagai metastatik yang tinggi. regulator EMT, seperti E-
macam media pertumbuhan. Kemampuan metastasis sel cadherin, Snail1, Twist2,
Sel ini dapat tumbuh dalam SKBR3 telah teruji ZEB1 dan ZEB2 (Cognart et
media pertumbuhan DMEM berdasarkan kemampuan al. 2020).
(Dulbecco’s Modified Eagle’s deformasinya, yaitu dengan Prevalensi pasien dengan
Medium) (Cognart et al., cara memberikan tekanan kanker payudara
2020; Mota et al., 2017); mekanik melalui saluran overekspresi HER2 yang
Roswell Park Memorial microfluidic sebagai analogi mengalami resistensi
Institute (RPMI) – 1640 (Prat pergerakan sel dalam aliran terhadap terapi tertarget
et al., 2013; Emlet et al., darah (Cognart et al. 2020). dengan inhibitor HER2
2006) dan McCoy's 5a (Liu et Selain itu, sel SKBR3 mampu seperti Trastuzumab
al., 2015), masing-masing melakukan perubahan diketahui cukup tinggi
dengan 10% Fetal Bovine morfologi yang dikenal (Sahlberg et al., 2013). Oleh
Serum (FBS). Berdasarkan dengan istilah epithelial-to- karena itu, penggunaan sel
Cell Line Service (CLS) GmbH, mesenchymal transition SKBR3 dapat bermanfaat
sel SKBR3 memiliki doubling (EMT). Kemampuan EMT untuk menjelaskan
time sekitar 30 jam. dari sel SKBR3 ini juga mekanisme resistensi
sejalan dengan peningkatan terhadap Trastuzumab serta
21
BioTrends Vol.11 No.2 Tahun 2020
22
BioTrends Vol.11 No.2 Tahun 2020
Tabel 2. Penggunaan sel MCF-7/HER2 sebagai model kanker payudara positif HER2
Referensi Temuan Penelitian
Adam et Stimulasi heregulin memicu interaksi fisik PAK1, aktin dan HER2 serta
al., 1998 interaksi ketiganya bergantung pada aktivasi PI-3 kinase.
Tari et al., HER2/neu menginduksi resistensi all-trans retinoic acid (ATRA) pada
2002 kanker payudara dengan memanfaatkan protein Grb2 dan Akt.
23
BioTrends Vol.11 No.2 Tahun 2020
Badve, S., Dabbs, D. J., Schnitt, Epidermal Growth Factor Coupled With Narrow
S. J., Baehner, F. L., Decker, Receptor in Triple-Negative Constrictions Induce Cell
T., Eusebi, V., Fox, S. B., and Basal-Like Breast Type-Dependent
Ichihara, S., Jacquemier, J., Cancer: Promising Clinical Morphological And
Lakhani, S. R., Palacios, J., Target or Only a Marker? Molecular Changes In SK-BR-
Rakha, E. A., Richardson, A. The Cancer Journal, 16(1), 3 And MDA-MB-231 Cells.
L., Schmitt, F. C., Tan, P.-H., 23–32. Scientific Report. 10:6386.
Tse, G. M., Weigelt, B., Ellis, Cailleau, R., Olivé, M., & Comşa, Ş., Cimpean, A. M., &
I. O., & Reis-Filho, J. S. Cruciger, Q. V. J. (1978). Raica, M. (2015). The story
(2011). Basal-like and triple- Long-term human breast of MCF-7 breast cancer cell
negative breast cancers: A carcinoma cell lines of line: 40 years of experience
critical review with an metastatic origin: in research. Anticancer
emphasis on the Preliminary characterization. Research, 35(6), 3147–3154.
implications for pathologists In Vitro, 14(11), 911–915. Čunderlíková, B., Vasovič, V.,
and oncologists. Modern Chavez, K. J., Garimella, S. V., & Sieber, F., Furre, T., Borgen,
Pathology, 24(2), 157–167. Lipkowitz, S. (2011). Triple E., Nesland, J. M., & Peng, Q.
Benz, C. C., Scott, G. K., Sarup, negative breast cancer cell (2011). Hexaminolevulinate-
J. C., Johnson, R. M., lines: One tool in the search mediated photodynamic
Tripathy, D., Coronado, E., for better treatment of purging of marrow grafts
Shepard, H. M., & Osborne, triple negative breast with murine breast
C. K. (1992). Estrogen- cancer. Breast Disease, carcinoma. Bone Marrow
dependent, tamoxifen- 32(1–2), 35–48. Transplantation, 46(8),
resistant tumorigenic Chiorazzo, M.G., Tunset, H.M., 1118–1127.
growth of MCF-7 cells Popov, A.V., Johansen, B., ECACC. (2017). Cell line profile:
transfected with HER2/neu. Moestue, S, Delikatny, E.J. MDA-MB-231 (ECACC
Breast Cancer Research and (2019): Detection and catalogue no. 92020424).
Treatment, 24(2), 85–95. Differentiation of Breast https://www.phe-
Bertucci, F., Finetti, P., Cervera, Cancer Sub-Types Using a culturecollections.org.uk/pr
N., Esterni, B., Hermitte, F., cPLA2α Activatable oducts/celllines/generalcell/
Viens, P., & Birnbaum, D. Fluorophore. Scientific detail.jsp?refId=92020424&c
(2008). How basal are triple- Report, 9:6122. ollection=ecacc_gc
negative breast cancers? Chung C. dan Lam MSH. (2013): Emlet DR, Schwartz R, Brown
International Journal of Pertuzumab for The KA , Pollice AA, Smith CA,
Cancer, 123(1), 236–240. Treatment of Human Shackney SE. (2006): HER2
Bos, P. D., Zhang, X. H.-F., Epidermal Growth Factor Expression As A Potential
Nadal, C., Shu, W., Gomis, R. Receptor Type 2-Positive Marker for Response to
R., Nguyen, D. X., Minn, A. J., Metastatic Breast Cancer. Therapy Targeted to The
van de Vijver, M. J., Gerald, American Journal of Health- EGFR. British Journal of
W. L., Foekens, J. A., & System Pharmacy, 70: 1579– Cancer, 94: 1144–1153.
Massagué, J. (2009). Genes 1587. Goldhirsch, A., Wood, W. C.,
that mediate breast cancer Chung, I., Reichelt, M., Shao, L., Coates, A. S., Gelber, R. D.,
metastasis to the brain. Akita, R. W., Koeppen, H., Thürlimann, B., & Senn, H.-J.
Nature, 459(7249), 1005– Rangell, L., Schaefer, G., (2011). Strategies for
1009. Mellman, I., & Sliwkowski, subtypes—dealing with the
Burdall, S. E., Hanby, A. M., M. X. (2016). High cell- diversity of breast cancer:
Lansdown, M. R., & Speirs, surface density of HER2 Highlights of the St Gallen
V. (2003). Breast cancer cell deforms cell membranes. International Expert
lines: Friend or foe? Breast Nature Communications, 7, Consensus on the Primary
Cancer Research, 5(2), 89. 12742. Therapy of Early Breast
Burness, M. L., Grushko, T. A., Cognart HA, Viovy JL, Villard C. Cancer 2011. Annals of
& Olopade, O. I. (2010). (2020): Fluid Shear Stress Oncology, 22(8), 1736–1747.
24
BioTrends Vol.11 No.2 Tahun 2020
Harrell, J. C., Pfefferle, A. D., Discovery. PLoS ONE, 4(7), cancer markers
Zalles, N., Prat, A., Fan, C., e6146. overexpressed in single
Khramtsov, A., Olopade, O. Kaur, P., Nagaraja, G. M., MCF7 cells using antibody
I., Troester, M. A., Dudley, A. Zheng, H., Gizachew, D., conjugated hollow gold
C., & Perou, C. M. (2014). Galukande, M., Krishnan, S., nanospheres. Biosensors
Endothelial-like properties & Asea, A. (2012). A mouse and Bioelectronics, 24(7),
of claudin-low breast cancer model for triple-negative 2260–2263.
cells promote tumor breast cancer tumor- Leirdal M, Shadidy M, Røsok O,
vascular permeability and initiating cells (TNBC-TICs) Sioud M. (2004):
metastasis. Clinical & exhibits similar aggressive Identification Of Genes
Experimental Metastasis, phenotype to the human Differentially Expressed In
31(1), 33–45. disease. BMC Cancer, 12(1), Breast Cancer Cell Line
Holliday, D. L., & Speirs, V. 120. SKBR3: Potential
(2011). Choosing the right Kenny, P. A., Lee, G. Y., Myers, Identification Of New
cell line for breast cancer C. A., Neve, R. M., Semeiks, Prognostic Biomarkers.
research. Breast Cancer J. R., Spellman, P. T., Lorenz, International Journal of
Research, 13(4), 215. K., Lee, E. H., Barcellos-Hoff, Molecular Medicine, 14 (2):
Huang G, Hobbs S, Walton M, M. H., Petersen, O. W., Gray, 217-222.
Epstein R (2002) Dominant J. W., & Bissell, M. J. (2007). Lelekakis, M., Moseley, J. M.,
Negative Knockout Of P53 The morphologies of breast Martin, T. J., Hards, D.,
Abolishes Erbb2-Dependent cancer cell lines in three- Williams, E., Ho, P., Lowen,
Apoptosis And Permits dimensional assays correlate D., Javni, J., Miller, F. R.,
Growth Acceleration In with their profiles of gene Slavin, J., & Anderson, R. L.
Human Breast Cancer Cells. expression. Molecular (1999). A novel orthotopic
British Journal of Cancer 86: Oncology, 1(1), 84–96. model of breast cancer
1104 – 1109. Kumar, R., Mandal, M., Lipton, metastasis to bone. Clinical
Incorvati, J. A., Shah, S., Mu, Y., A., Harvey, H., & Thompson, & Experimental Metastasis,
& Lu, J. (2013). Targeted C. B. (1996). Overexpression 17(2), 163–170.
therapy for HER2 positive of HER2 modulates bcl-2, Li, E., Lin, L., Chen, C.-W., & Ou,
breast cancer. Journal of bcl-XL, and tamoxifen- D.-L. (2019). Mouse Models
Hematology & Oncology, induced apoptosis in human for Immunotherapy in
6(1), 38. MCF-7 breast cancer cells. Hepatocellular Carcinoma.
Kang, Y., Siegel, P. M., Shu, W., Clinical Cancer Research, Cancers, 11(11), 1800.
Drobnjak, M., Kakonen, S. 2(7), 1215–1219. Liu, D., Yang, Z., Wang, T.,
M., Cordón-Cardo, C., Guise, Kuperwasser, C., Chavarria, T., Chen, H., Hu, Y., Hu, C., Guo,
T. A., & Massagué, J. (2003). Wu, M., Magrane, G., Gray, L., Deng, Q., Liu, Y., & Yu, M.
A multigenic program J. W., Carey, L., Richardson, (2016). Β2-AR signaling
mediating breast cancer A., & Weinberg, R. A. (2004). controls trastuzumab
metastasis to bone. Cancer From The Cover: resistance-dependent
Cell, 3(6), 537–549. Reconstruction of pathway. Oncogene, 35(1),
Kao, J., Salari, K., Bocanegra, functionally normal and 47.
M., Choi, Y.-L., Girard, L., malignant human breast Liu, H., Zang, C., Fenner, M. H.,
Gandhi, J., Kwei, K. A., tissues in mice. Proceedings Possinger, K., & Elstner, E.
Hernandez-Boussard, T., of the National Academy of (2003). PPARγ Ligands and
Wang, P., Gazdar, A. F., Sciences, 101(14), 4966– ATRA Inhibit the Invasion of
Minna, J. D., & Pollack, J. R. 4971. Human Breast Cancer Cells
(2009). Molecular Profiling Lee, S., Chon, H., Lee, M., Choo, in vitro. Breast Cancer
of Breast Cancer Cell Lines J., Shin, S. Y., Lee, Y. H., Son, Research and Treatment,
Defines Relevant Tumor S. W., & Oh, C. H. (2009). 79(1), 63–74.
Models and Provides a Surface-enhanced Raman Mawatari T, Ninomiya I,
Resource for Cancer Gene scattering imaging of HER2 Inokuchi M, Harada S,
25
BioTrends Vol.11 No.2 Tahun 2020
Hayash H, et al. (2015): Marques, M. M. C. (2017). Herschkowitz, J. I., He, X., &
Valproic Acid Inhibits Molecular characterization Perou, C. M. (2010).
Proliferation Of HER2- of breast cancer cell lines by Phenotypic and molecular
Expressing Breast Cancer clinical characterization of the
Cells By Inducing Cell Cycle immunohistochemical claudin-low intrinsic subtype
Arrest And Apoptosis markers. Oncology Letters, of breast cancer. Breast
Through Hsp70 Acetylation. 13(6), 4708–4712. Cancer Research, 12(5), R68.
International Journal Of Neve, R. M., Chin, K., Fridlyand, Pulaski, B. A., Clements, V. K.,
Oncology 47: 2073-2081 J., Yeh, J., Baehner, F. L., Pipeling, M. R., & Ostrand-
Mendes, D., Alves, C., Afonso, Fevr, T., Clark, L., Bayani, N., Rosenberg, S. (2000a).
N., Cardoso, F., Passos- Coppe, J.-P., Tong, F., Speed, Immunotherapy with
Coelho, J. L., Costa, L., T., Spellman, P. T., DeVries, vaccines combining MHC
Andrade, S., & Batel- S., Lapuk, A., Wang, N. J., class II/CD80 + tumor cells
Marques, F. (2015). The Kuo, W.-L., Stilwell, J. L., with interleukin-12 reduces
benefit of HER2-targeted Pinkel, D., Albertson, D. G., established metastatic
therapies on overall survival Gray, J. W. (2006). A disease and stimulates
of patients with metastatic collection of breast cancer immune effectors and
HER2-positive breast cancer cell lines for the study of monokine induced by
– a systematic review. functionally distinct cancer interferon γ. Cancer
Breast Cancer Research, subtypes. Cancer Cell, 10(6), Immunology,
17(1). 515–527. Immunotherapy, 49(1), 34–
Merkhofer EC, Cogswell P, Perou, C. M., Jeffrey, S. S., van 45.
Baldwin AS (2010) Her2 de Rijn, M., Rees, C. A., Pulaski, B. A., & Ostrand-
activates NF-kappaB and Eisen, M. B., Ross, D. T., Rosenberg, S. (1998).
induces invasion through Pergamenschikov, A., Reduction of Established
the canonical pathway Williams, C. F., Zhu, S. X., Spontaneous Mammary
involving IKK alpha. Lee, J. C. F., Lashkari, D., Carcinoma Metastases
Oncogene 29: 1238–1248 Shalon, D., Brown, P. O., & following Immunotherapy
Minn, A. J., Gupta, G. P., Siegel, Botstein, D. (1999). with Major
P. M., Bos, P. D., Shu, W., Distinctive gene expression Histocompatibility Complex
Giri, D. D., Viale, A., Olshen, patterns in human Class II and B7.1 Cell-based
A. B., Gerald, W. L., & mammary epithelial cells Tumor Vaccines. Cancer
Massagué, J. (2005a). Genes and breast cancers. Research, 58(7), 1486–1493.
that mediate breast cancer Proceedings of the National Pulaski, B. A., & Ostrand‐
metastasis to lung. Nature, Academy of Sciences, 96(16), Rosenberg, S. (2000). Mouse
436(7050), 518–524. 9212–9217. 4T1 Breast Tumor Model.
Minn, A. J., Kang, Y., Serganova, Perou, Charles M., Sørlie, T., Current Protocols in
I., Gupta, G. P., Giri, D. D., Eisen, M. B., van de Rijn, M., Immunology, 39(1).
Doubrovin, M., Ponomarev, Jeffrey, S. S., Rees, C. A., https://doi.org/10.1002/047
V., Gerald, W. L., Blasberg, Pollack, J. R., Ross, D. T., 1142735.im2002s39
R., & Massagué, J. (2005b). Johnsen, H., Akslen, L. A., Pulaski, B. A., Terman, D. S.,
Distinct organ-specific Fluge, Ø., Pergamenschikov, Khan, S., Muller, E., &
metastatic potential of A., Williams, C., Zhu, S. X., Ostrand-Rosenberg, S.
individual breast cancer cells Lønning, P. E., Børresen- (2000b). Cooperativity of
and primary tumors. Journal Dale, A.-L., Brown, P. O., & Staphylococcal aureus
of Clinical Investigation, Botstein, D. (2000). Enterotoxin B Superantigen,
115(1), 44–55. Molecular portraits of Major Histocompatibility
Mota, A. de L., Evangelista, A. human breast tumours. Complex Class II, and CD80
F., Macedo, T., Oliveira, R., Nature, 406(6797), 747–752. for Immunotherapy of
Scapulatempo-Neto, C., Prat, A., Parker, J. S., Karginova, Advanced Spontaneous
Vieira, R. A. da C., & O., Fan, C., Livasy, C., Metastases in a Clinically
26
BioTrends Vol.11 No.2 Tahun 2020
27
BioTrends Vol.11 No.2 Tahun 2020
28